Osteosarcoma is a diagnosis no family should ever have to face. It is the most common primary bone cancer in children and adolescents, yet treatment options have hardly changed in four decades, while outcomes remain devastating for those with relapsed or metastatic disease. Families searching for answers often discover a painful truth that while science has advanced rapidly for many cancers, innovation for rare pediatric cancers continues to lag behind.

Today, a profound shift is underway. Advances in artificial intelligence (AI) and machine learning are giving researchers new tools to decode osteosarcoma biology, identify new therapeutic targets, and design more precise treatments. For the first time, technology may allow progress to move at a pace that reflects the urgency felt by patients, caregivers, and clinicians.

At OS Therapies, our mission is to bring transformative, mechanism-driven treatments for osteosarcoma. AI is reshaping how we approach this work. What once required years of trial-and-error experimentation can now be informed by computational models capable of processing biological complexity at scale, giving our teams greater confidence in the data and direction ahead.

Why Osteosarcoma Needed New Tools

Despite decades of effort, survival outcomes for children with metastatic or recurrent osteosarcoma remain largely unchanged since the 1980s. Standard treatments rely heavily on chemotherapy and surgery, and while some patients respond, many do not. The tumor’s underlying biology is extraordinarily complex. It is genetically unstable, heterogeneous, and marked by a high degree of molecular chaos.

Traditional drug development struggles in this environment. When a cancer has dozens, and sometimes hundreds, of genomic alterations, which ones matter? Which signaling pathways drive progression? Why do some patients respond to therapy while others don’t? AI offers a platform to help answer these questions with unprecedented clarity.

AI as a Discovery Engine

Classical research approaches test one hypothesis at a time, but AI examines millions of data points simultaneously. In fact, AI systems can process genomic, proteomic, and imaging data together, revealing biological patterns that would be impossible to see through traditional, hypothesis-by-hypothesis research. This matters enormously in osteosarcoma, where the biology often appears noisy or contradictory when viewed through a single lens.

Integrating disparate datasets through AI helps researchers distinguish the mutations that truly drive disease progression from those that are simply byproducts of the tumor’s inherent instability. These models can also capture the dynamic interplay between osteosarcoma cells and the immune system, an area of growing importance as immuno-oncology strategies gain momentum. They can even simulate how emerging drug candidates might interact with specific molecular targets before a single experiment begins.

Ultimately, for rare diseases where patient samples are limited, these tools offer a powerful advantage, enabling scientists to extract meaning from complexity and accelerate progress with greater clarity and confidence.

From Data to Action: The OS Therapies Model

At OS Therapies, AI is embedded across multiple stages of our scientific process, from early target selection to therapeutic design and critical go/no-go decisions. Steps that once took years of sequential experimentation can now be guided by data-driven modeling from the outset.

Because osteosarcoma tumors differ so dramatically, even within the same patient, AI allows us to model disease complexity at scale, anticipate resistance mechanisms, and design therapies with far greater precision.

In the development of OST-HER2, AI-enabled modeling has helped our teams rapidly generate, test, and refine therapeutic hypotheses before committing to time and resource-intensive experiments. Rather than advancing one idea at a time, we can evaluate multiple strategies in parallel, narrowing the most promising paths in weeks instead of months.

Looking ahead, the role of AI will only expand. If and when OST-HER2 reaches patients, these same tools will be critical for understanding response patterns, identifying opportunities for combination strategies, and continuously improving how the therapy is used. In this way, AI extends learning far beyond approval, guiding how therapies are continually refined and strengthened in real-world use.

AI and the Immune Response: A New Window into Pediatric Cancers

One of the most promising applications of AI in rare cancers is in understanding the immune environment. Osteosarcoma’s interaction with the immune system has long been recognized but poorly understood. Traditional laboratory methods simply couldn’t untangle the constant interplay between tumor cells, immune cells, cytokines, and stromal components.

AI-driven models are now helping to:

• Map tumor-immune interactions at a single-cell level
• Identify immune evasion signatures
• Predict which patients may benefit most from immunotherapy
• Guide the design of more targeted, less toxic immune-based treatments

In a disease where immunotherapy has historically struggled to gain traction, this new level of clarity is essential.

Supporting Researchers, Clinicians, and Families

The value of AI also extends beyond drug development itself. Researchers can explore new hypotheses faster and at lower cost, while clinicians may soon gain access to predictive tools that offer clearer insight into recurrence or metastatic risk. As these technologies evolve, families also stand to benefit from more personalized diagnostic guidance.

At the same time, researchers remain at the center of every discovery. AI simply helps them work with more information and a clearer picture of the disease, allowing osteosarcoma to be approached with the same computational rigor now transforming genomics, imaging, and precision immunotherapy.

A Future Where Technology Catches Up to Urgency

For years, progress in osteosarcoma has been held back by how little the science could reveal. Today, new computational tools are beginning to widen that view, helping researchers uncover patterns and possibilities that were once harder to discern. With clearer insight, the field can move toward discoveries that feel more responsive to what patients and families urgently need.

And while technology will never replace the compassion, expertise, or daily courage that define this community, it can support the people doing this work by offering new ways to understand the disease, and new opportunities to push the science forward.

This moment feels like a beginning. As scientists embrace new tools and gain new clarity, there is real potential for the field to move closer to the kind of progress osteosarcoma patients have waited decades to see.

Author Bio: Gerald Commissiong Chief Business Officer, OS Therapies   is healthcare executive with over 15 years of experience serving in C-suite roles in emerging growth companies developing and commercializing novel therapeutics, diagnostics and natural products to address acute and chronic diseases. He previously served as President & CEO of Amarantus Bioscience Holdings, Inc. and Todos Medical, Ltd. helping raise over $70 million in equity and debt capital. His experience spans neurology, regenerative medicine, oncology and infectious disease. Mr. Commissiong received a BS in Management Science & Engineering with a focus on financial decisions from Stanford University and played professional football in the Canadian Football League for the Calgary Stampeders.